

Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab)

Catalog # APR11619

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P04626 & P21860
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	ERBB2 / HER2 / CD340,ERBB3 / HER3
Expression system	CHO

Protein Information

Images




Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) is 100.00%, determined by SEC-HPLC.


Zenocutuzumab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zenocutuzumab bound to hu-HER2-his, and




the EC50 was 0.017 nM.




Zenocutuzumab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Zenocutuzumab bound to BT474 cells, and the EC50 was 1.277 nM.



Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and the EC50 was 0.879 nM.



Co-incubation of Zenocutuzumab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zenocutuzumab. As shown in fig, Zenocutuzumab has ADCC activity, and the IC50 was 0.031 nM.



The detected molecular weight of Anti-HER2 & HER3 Reference Antibody (Zenocutuzumab) is 145.20 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.